... Food and Drug Administration (FDA) approved a formulation of mitomycin called Zusduri, which is specifically indicated for treating recurrent low-grade intermediate-risk NMIBC.In 2025, the FDA also approved Inlexzo, a gemcitabine-based intravesical system, for treating adults with BCG-unresponsive NMIBC with carcinoma in situ (CIS), with or without ...
7 Bladder Cancer Treatment Options: Surgery, Immunotherapy, Chemo, and More
... Food and Drug Administration (FDA) approved a formulation of mitomycin called Zusduri, which is specifically indicated for treating recurrent low-grade intermediate-risk NMIBC.In 2025, the FDA also approved Inlexzo, a gemcitabine-based intravesical system, for treating adults with BCG-unresponsive NMIBC with carcinoma in situ (CIS), with or without ...